mRNA Series
For mRNA vaccines, mRNA therapeutics, and delivery systems, the substantial differences in their mechanisms of action and molecular types lead to distinct evaluation objectives and requirements for their preclinical pharmacokinetic (PK) studies. To address these specific needs, we’ve developed a range of strategies for preclinical PK evaluation of mRNA drugs, drawing on hands-on experience, cutting-edge literature, and guidelines. We also provide a detailed interpretation of the preclinical PK data of FDA-approved mRNA vaccines.
-
Novel Drug Modalities
-
Therapeutic Areas
-
Strategies for Preclinical PK Evaluation of mRNA-Based Therapeutics: mRNA Vaccines, mRNA Therapeutic Drugs, and Novel Excipients
ArticlesDec 08,2023Learn More
-
mRNA-Based Vaccines and Therapeutics Shorten the Development Cycle with WuXi AppTec DMPK Services
BrochuresJan 04,2024Learn More -
Comparison of Branched DNA (B-DNA) and Polymerase Chain Reaction (RT-qPCR) Method Validation for the Quantification of mRNA Therapeutics in Plasma
PostersJan 12,2024Learn More -
FDA Approved mRNA Vaccines: Interpretation of Preclinical Pharmacokinetic (PK) Data
ArticlesDec 19,2023Learn More -
What is mRNA Vaccines and Its Future?
ArticlesDec 08,2023Learn More -
Evaluation of mRNA Capping Efficiency by Liquid Chromatography Coupled to High Resolution and Accurate Mass Spectrometry
PostersJun 01,2023Learn More
The mRNA Series Keeps You in The Know
You don't need to attend mRNA events frequently to grow your knowledge of the pharmacokinetics of mRNA. Get industry knowledge, articles, and other resources delivered straight to your inbox.
Related Service
Stay Connected
Keep up with the latest news and insights.
